Antacids Market
Antacids Market Study by Proton Pump Inhibitors, H2 Antagonists, and Acid Neutralizers for Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies from 2023 to 2033
Analysis of Antacids Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Antacids Market Outlook (2023 to 2033)
In 2023, the global antacids market is valued at US$ 14 billion and is expected to reach a market size of US$ 22 billion by 2033. The market is forecasted to increase at a CAGR of 4.6% from 2023 to 2033, according to Fact.MR.
- Sales of antacids through online pharmacies are expected to increase faster at a CAGR of 5% over the forecast period due to the rising popularity of the online shopping culture.
- High penetration of smartphones and improvements in telecom services are also driving antacid sales through online pharmacies.
Antacids are over-the-counter (OTC) drugs that reduce indigestion and heartburn by neutralizing the stomach's acid. They are widely offered in easy-to-chew tablet, powder, and liquid forms.
Antacids are extensively used to treat a painful stomach and the discomfort associated with dyspepsia, stomach ulcers, inflammation, acid reflux, and an upset stomach. They help to shield the stomach lining from the esophagus, the duodenum, and the harsh acids produced during digestion. These are self-prescribed drugs that work by reducing stomach acid and inhibiting pepsin.
Global demand for antacids rises as a result of several factors, including bad eating habits, sedentary lifestyles, and regular use of medications to manage high blood pressure. Market players are investing heavily in research and development initiatives to differentiate their products by developing effective antacids.
Manufacturers in the antacids market are approaching drug formulation techniques through consumer-centric means, in the form of chewable and flavored tablets. Lenient legislation regarding the over-the-counter (OTC) availability of antacids is complementing the penetration of antacids through retail pharmacies, convenience stores, and hospital pharmacies.
One of the main reasons driving market expansion is the rising incidence of gastroesophageal reflux disease (GERD). Antacids are extensively used since they are affordable and help to reduce the discomfort, irritation, swelling, and inflammation caused by heartburn.
An increase in product advancements, such as the creation of powerful and safe raft-forming antacids that offer improved efficacy and a longer duration of action, is boosting market expansion. The market is expected to develop as a result of the increasing use of chewable tablets in a variety of flavors that are convenient to store, deliver the right dosage, and enhance patient adherence.
Easy product accessibility through e-Commerce platforms, an expanding geriatric population that is vulnerable to acidic issues, and the rising prevalence of heartburn among the overall population are all contributing to market expansion. The usage of antacids is increasing because many individuals rely on ready-to-eat foods due to a hectic lifestyle.
Report Attributes |
Details |
|
Antacids Market Size (2023) |
US$ 14 Billion |
|
Projected Market Value (2033) |
US$ 22 Billion |
|
Global Market Growth Rate (2023 to 2033) |
4.6% CAGR |
|
Market Share of Tablets (2023) |
50% |
|
Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Which are the Key Aspects Driving the Sales of Antacids?
“Rising Incidence of GERD in Geriatric Population”
Rising elderly population with gastroesophageal reflux disease (GERD) is one of the factors driving market expansion. As the elderly are particularly susceptible to peptic ulcers and gastroesophageal reflux disease, the growing geriatric population is one of the most promising development factors for the antacids industry. It is predicted that the geriatric population will suffer a rise in GERD, which will raise the demand for antacids.
Symptomatic conditions, including Barrett's esophagus and esophageal cancer, are usually present in the geriatric population. An array of therapies are employed to treat these problems, and antacid use has greatly increased in these circumstances, which is anticipated to fuel market expansion over the coming years.
“Growing Prevalence of Gastrointestinal Issues”
The global market for antacids is being driven by the rising prevalence of gastrointestinal issues. The adoption of sedentary lifestyles also contributes to several acidity-related issues. Because of this, customers are turning to antacids and other digestion aids. As a result, antacid medications are sold over the counter and come in a variety of flavors at a reasonable price.
Increased emphasis on the release of high-quality medications and rising demand for early diagnosis among consumers are anticipated to boost market growth throughout the forecast period. Rising awareness of the early signs of gastrointestinal illnesses is also positive for market expansion.
“Increasing Popularity of Mouth-melting Antacids”
A new development in the antacid industry is the use of mouth-melting antacids. Until now, antacids could only be found in tablet, liquid, or powder form; however, researchers have now developed mouth-melting antacids, which are composed of tiny mouth-melting granules that quickly dissolve in the mouth. These effervescent granules that are found in antacids do their function.
- Sunpharma's 'Pepmelt', which combines the benefits of the herbal components it contains with modern mouth-melting technology, is an example of a mouth-melting quick relief antacid.
Nowadays, natural plant extracts to reduce stomach acidity are used to create antacid medication compositions. For the treatment of issues associated with acidity, OTC herbal and traditional medicines are used.
What are the Challenges Faced by Antacid Providers?
“Availability of Antacid Substitutes and Lack of Awareness of Acidity Symptoms”
Pricing trends indicate that high costs of raw materials are impeding market expansion. Key raw materials such as calcium carbonate and magnesium hydroxide have seen a price increase recently.
The market for antacids is also being challenged by a rise in regulations that are being enforced by governments all over the world. These rules, which are intended to ensure consumer safety, will probably continue to present difficulties for businesses.
The availability of antacid substitutes and a lack of awareness of acidity symptoms are predicted to hamper market expansion. Market growth is anticipated to be constrained by several factors, including side effects such as constipation, a laxative effect, and allergic responses.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
How Can Start-ups Gain Profits in This Competitive Space?
“New Entrants Introducing More Effective and Long-lasting Antacids”
New companies are offering more effective and long-lasting antacids. Emerging market players are introducing new flavors to meet consumers' constantly shifting preferences.
- A start-up based in Austin, Wonderbelly, offers effective, more environment-friendly, and cleaner digestive health medication. This antacid is non-GMO and free of talc, colors, and other harmful substances. Wonderbelly promises to utilize healthier ingredients and provides FDA-approved over-the-counter goods that are 100% plastic-free.
Why is Europe Dominating the Global Antacids Market?
“Increasing Government Initiatives for Early Detection & Gastrointestinal Bleeding Treatment”
- Europe is the leading regional antacids market with 50% share at present.
Rising sales of antacids through online pharmacies and the presence of top antacid manufacturers are boosting market value in the region. Increasing government initiatives for early detection and gastrointestinal bleeding treatment are supporting market expansion.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Country-wise Insights
Will the United States Be an Investment-worthy Market for Manufacturers of Antacids?
“Presence of Advanced Pharmaceutical Laboratories”
The market in the United States is driven by the presence of advanced pharmaceutical laboratories and the growing popularity of self-medication. The market in the United States is anticipated to grow as a result of the rising incidence of GERD due to lifestyle changes. Antacid medications are projected to be in demand in the United States due to the rising frequency of gastrointestinal illnesses.
What is Driving Antacid Demand across Germany?
“Favorable Reimbursement Policies”
The market in Germany is expanding because of the rising geriatric population, excessive consumption of unhealthy foods, and favorable reimbursement policies. An increase in efforts by pharmaceutical companies to raise awareness about acidity symptoms and the high demand for over-the-counter digestive medicines are factors driving market growth.
Why are Sales of Antacids High in Japan?
“Presence of Well-developed Healthcare Infrastructure”
Market growth in Japan is attributed to the presence of a well-developed healthcare infrastructure, rising disposable income, and an expanding pharmaceutical industry. Growing consumer awareness about antacids, the presence of advanced diagnostic services, and the availability of efficient treatment options are some of the key factors driving market expansion.
Category-wise Insights
Which Formulation is Estimated to Contribute to Substantial Market Revenue Share?
“Tablets Preferred Owing to Ease of Consumption and Storage Convenience”
By formulation, the market is segmented into tablets, liquid, powder, and others.
- Tablets account for 50% share of the global market in 2023.
Convenience is a significant feature leading to an increase in the demand for antacids in the tablet format. Tablets will remain the leading choice of consumers suffering from GERD, owing to their administered dosage, ease of consumption, and storage convenience. The availability of leading drug classes in the tablet format is further adding sheen to the growing popularity of tablets in the market.
Why are Online Pharmacies Widely Preferred for Buying Antacids?
“Convenience of Home Delivery of Therapeutics”
Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
Online pharmacies are favored by customers due to their appealing marketing, price savings, easy access to pharmaceuticals, and home delivery options. Online pharmacies are becoming a standard distribution route for antacids. Online sales are on the rise in the worldwide antacids industry, which is dominated by over-the-counter (OTC) medications that don't need a prescription.
The main factor in the growth of e-Commerce retailing has been the efforts made by the retailers to enhance the online buying experience through improved online education and targeted marketing. Sales of antacids are further boosted by the robust viability of e-Commerce platforms. Internet merchants also provide free access to various online deals.
Competitive Landscape
Leading companies are embracing tactics, including strategic alliances, quality control, acquisitions, product standards, supply chain management, and collaborations, to increase their geographic reach and improve their competitive position. Top antacid producers are focusing on new developments and introducing new products while following safety regulations to meet consumer demand.
For instance,
- In 2020, Horizon Therapeutics PLC's Vimovo delayed-release tablets were introduced by Lupin. The medication is used to lower the risk of stomach ulcers caused by naproxen.
Key Segments Covered in Antacids Industry Research
-
By Drug Class :
- Proton Pump Inhibitors
- H2 Antagonists
- Acid Neutralizers
-
By Formulation :
- Tablets
- Liquid
- Powder
- Others
-
By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
-
By Region :
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Table of Content
1. Preface 1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary : Global Market 4. Market Overview 4.1. Introduction 4.1.1. Product Definition 4.1.2. Industry Evolution / Developments 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunity 4.4. Global Market Value (US$ Mn) Forecast, 2023 - 2033 4.5. Porter’s Five Force Analysis 4.6. Value Chain Analysis 4.7. Market Outlook 5. Global Market Analysis and Forecasts, By Drug Class 5.1. Introduction & Definition 5.2. Key Findings / Developments 5.3. Key Trends 5.4. Market Value (US$ Mn) Forecast By Drug Class, 2023-2033 5.4.1. Proton pump inhibitors 5.4.2. H2 Antagonist 5.4.3. Acid neutralizers 5.5. Market Attractiveness By Drug Class 6. Global Market Analysis and Forecasts, By Formulation 6.1. Introduction & Definition 6.2. Key Findings / Developments 6.3. Key Trends 6.4. Market Value (US$ Mn) Forecast By Formulation, 2023-2033 6.4.1. Tablet 6.4.2. Liquid 6.4.3. Powder 6.4.4. Others 6.5. Market Attractiveness By Formulation 7. Global Market Analysis and Forecasts, By Distribution Channel 7.1. Introduction & Definition 7.2. Key Findings / Developments 7.3. Key Trends 7.4. Market Value (US$ Mn) Forecast By Distribution Channel, 2023-2033 7.4.1. Hospital Pharmacies 7.4.2. Retail Pharmacies 7.4.3. Others 7.5. Market Attractiveness By Distribution Channel 8. Global Market Analysis and Forecasts, By Region 8.1. Key Findings 8.2. Market Value (US$ Mn) Forecast By Region 8.2.1. North America 8.2.2. Europe 8.2.3. Asia Pacific 8.2.4. Latin America 8.2.5. Middle East and Africa 8.3. Market Attractiveness By Country/Region 9. North America Market Analysis and Forecast 9.1. Introduction 9.1.1. Key Findings 9.1.2. Key Trends 9.2. Market Value (US$ Mn) Forecast By Drug Class, 2023-2033 9.2.1. Proton pump inhibitors 9.2.2. H2 Antagonist 9.2.3. Acid neutralizers 9.3. Market Value (US$ Mn) Forecast By Formulation, 2023-2033 9.3.1. Tablet 9.3.2. Liquid 9.3.3. Powder 9.3.4. Others 9.4. Market Value (US$ Mn) Forecast By Distribution Channel, 2023-2033 9.4.1. Hospital Pharmacies 9.4.2. Retail Pharmacies 9.4.3. Others 9.5. Market Value (US$ Mn) Forecast By Country, 2023-2033 9.5.1. U.S. 9.5.2. Canada 9.6. Market Attractiveness Analysis 9.6.1. By Drug Class 9.6.2. By Formulation 9.6.3. By Distribution Channel 9.6.4. By Country 10. Europe Market Analysis and Forecast 10.1. Introduction 10.1.1. Key Findings 10.1.2. Key Trends 10.2. Market Value (US$ Mn) Forecast By Drug Class, 2023-2033 10.2.1. Proton pump inhibitors 10.2.2. H2 Antagonist 10.2.3. Acid neutralizers 10.3. Market Value (US$ Mn) Forecast By Formulation, 2023-2033 10.3.1. Tablet 10.3.2. Liquid 10.3.3. Powder 10.3.4. Others 10.4. Market Value (US$ Mn) Forecast By Distribution Channel, 2023-2033 10.4.1. Hospital Pharmacies 10.4.2. Retail Pharmacies 10.4.3. Others 10.5. Market Value (US$ Mn) Forecast By Country, 2023-2033 10.5.1. U.K. 10.5.2. Germany 10.5.3. France 10.5.4. Spain 10.5.5. Italy 10.5.6. Rest of Europe 10.6. Market Attractiveness Analysis 10.6.1. By Drug Class 10.6.2. By Formulation 10.6.3. By Distribution Channel 10.6.4. By Country 11. Asia Pacific Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.1.2. Key Trends 11.2. Market Value (US$ Mn) Forecast By Drug Class, 2023-2033 11.2.1. Proton pump inhibitors 11.2.2. H2 Antagonist 11.2.3. Acid neutralizers 11.3. Market Value (US$ Mn) Forecast By Formulation, 2023-2033 11.3.1. Tablet 11.3.2. Liquid 11.3.3. Powder 11.3.4. Others 11.4. Market Value (US$ Mn) Forecast By Distribution Channel, 2023-2033 11.4.1. Hospital Pharmacies 11.4.2. Retail Pharmacies 11.4.3. Others 11.5. Market Value (US$ Mn) Forecast By Country, 2023-2033 11.5.1. India 11.5.2. China 11.5.3. Japan 11.5.4. Australia & New Zealand 11.5.5. Rest of Aisa Pacific 11.6. Market Attractiveness Analysis 11.6.1. By Drug Class 11.6.2. By Formulation 11.6.3. By Distribution Channel 11.6.4. By Country 12. Latin America Market Analysis and Forecast 12.1. Introduction 12.1.1. Key Findings 12.1.2. Key Trends 12.2. Market Value (US$ Mn) Forecast By Drug Class, 2023-2033 12.2.1. Proton pump inhibitors 12.2.2. H2 Antagonist 12.2.3. Acid neutralizers 12.3. Market Value (US$ Mn) Forecast By Formulation, 2023-2033 12.3.1. Tablet 12.3.2. Liquid 12.3.3. Powder 12.3.4. Others 12.4. Market Value (US$ Mn) Forecast By Distribution Channel, 2023-2033 12.4.1. Hospital Pharmacies 12.4.2. Retail Pharmacies 12.4.3. Others 12.5. Market Value (US$ Mn) Forecast By Country, 2023-2033 12.5.1. Brazil 12.5.2. Mexico 12.5.3. Rest of Latin America 12.6. Market Attractiveness Analysis 12.6.1. By Drug Class 12.6.2. By Formulation 12.6.3. By Distribution Channel 12.6.4. By Country 13. Middle East and Africa Market Analysis and Forecast 13.1. Introduction 13.1.1. Key Findings 13.1.2. Key Trends 13.2. Market Value (US$ Mn) Forecast By Drug Class, 2023-2033 13.2.1. Proton pump inhibitors 13.2.2. H2 Antagonist 13.2.3. Acid neutralizers 13.3. Market Value (US$ Mn) Forecast By Formulation, 2023-2033 13.3.1. Tablet 13.3.2. Liquid 13.3.3. Powder 13.3.4. Others 13.4. Market Value (US$ Mn) Forecast By Distribution Channel, 2023-2033 13.4.1. Hospital Pharmacies 13.4.2. Retail Pharmacies 13.4.3. Others 13.5. Market Value (US$ Mn) Forecast By Country, 2023-2033 13.5.1. South Africa 13.5.2. Saudi Arabia 13.5.3. Rest of MEA 13.6. Market Attractiveness Analysis 13.6.1. By Drug Class 13.6.2. By Formulation 13.6.3. By Distribution Channel 13.6.4. By Country 14. Competition Landscape 14.1. Market Players 14.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy) 14.2.1. AstraZeneca 14.2.1.1. Company Overview (HQ, Business Segments, Employee Strength) 14.2.1.2. Business Overview 14.2.1.3. Product Portfolio 14.2.1.4. Financial Overview 14.2.1.5. SWOT Analysis 14.2.1.6. Strategic overview 14.2.2. Bayer AG 14.2.2.1. Company Overview (HQ, Business Segments, Employee Strength) 14.2.2.2. Business Overview 14.2.2.3. Product Portfolio 14.2.2.4. Financial Overview 14.2.2.5. SWOT Analysis 14.2.2.6. Strategic overview 14.2.3. Boehringer Ingelheim GmbH 14.2.3.1. Company Overview (HQ, Business Segments, Employee Strength) 14.2.3.2. Business Overview 14.2.3.3. Product Portfolio 14.2.3.4. Financial Overview 14.2.3.5. SWOT Analysis 14.2.3.6. Strategic overview 14.2.4. Dr. Reddy’s Laboratories Ltd. 14.2.4.1. Company Overview (HQ, Business Segments, Employee Strength) 14.2.4.2. Business Overview 14.2.4.3. Product Portfolio 14.2.4.4. Financial Overview 14.2.4.5. SWOT Analysis 14.2.4.6. Strategic overview 14.2.5. GlaxoSmithKline plc 14.2.5.1. Company Overview (HQ, Business Segments, Employee Strength) 14.2.5.2. Business Overview 14.2.5.3. Product Portfolio 14.2.5.4. Financial Overview 14.2.5.5. SWOT Analysis 14.2.5.6. Strategic overview 14.2.6. Johnson & Johnson 14.2.6.1. Company Overview (HQ, Business Segments, Employee Strength) 14.2.6.2. Business Overview 14.2.6.3. Product Portfolio 14.2.6.4. Financial Overview 14.2.6.5. SWOT Analysis 14.2.6.6. Strategic overview 14.2.7. Pfizer Inc. 14.2.7.1. Company Overview (HQ, Business Segments, Employee Strength) 14.2.7.2. Business Overview 14.2.7.3. Product Portfolio 14.2.7.4. Financial Overview 14.2.7.5. SWOT Analysis 14.2.7.6. Strategic overview 14.2.8. Procter & Gamble 14.2.8.1. Company Overview (HQ, Business Segments, Employee Strength) 14.2.8.2. Business Overview 14.2.8.3. Product Portfolio 14.2.8.4. Financial Overview 14.2.8.5. SWOT Analysis 14.2.8.6. Strategic overview 14.2.9. Reckitt Benckiser Group plc 14.2.9.1. Company Overview (HQ, Business Segments, Employee Strength) 14.2.9.2. Business Overview 14.2.9.3. Product Portfolio 14.2.9.4. Financial Overview 14.2.9.5. SWOT Analysis 14.2.9.6. Strategic overview 14.2.10. Sanofi 14.2.10.1. Company Overview (HQ, Business Segments, Employee Strength) 14.2.10.2. Business Overview 14.2.10.3. Product Portfolio 14.2.10.4. Financial Overview 14.2.10.5. SWOT Analysis 14.2.10.6. Strategic overview 14.2.11. Sun Pharmaceuticals Ltd 14.2.11.1. Company Overview (HQ, Business Segments, Employee Strength) 14.2.11.2. Business Overview 14.2.11.3. Product Portfolio 14.2.11.4. Financial Overview 14.2.11.5. SWOT Analysis 14.2.11.6. Strategic overview 14.2.12. Takeda Pharmaceutical 14.2.12.1. Company Overview (HQ, Business Segments, Employee Strength) 14.2.12.2. Business Overview 14.2.12.3. Product Portfolio 14.2.12.4. Financial Overview 14.2.12.5. SWOT Analysis 14.2.12.6. Strategic overview 14.2.13. Valeant Pharmaceuticals International, Inc. 14.2.13.1. Company Overview (HQ, Business Segments, Employee Strength) 14.2.13.2. Business Overview 14.2.13.3. Product Portfolio 14.2.13.4. Financial Overview 14.2.13.5. SWOT Analysis 14.2.13.6. Strategic overview
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Size (US$ Mn) Forecast, By Drug Class, 2018–2033
Table 02: Global Market Size (US$ Mn) Forecast, By Formulation, 2023-2033
Table 03: Global Market Size (US$ Mn) Forecast, By Distribution Channel, 2018–2033
Table 04: Global Market (US$ Mn) Forecast, By Region, 2018–2033
Table 05: North America Market Size (US$ Mn) Forecast, by Drug Class, 2018–2033
Table 06: North America Market Size (US$ Mn) Forecast, by Formulation, 2018–2033
Table 07: North America Market Size (US$ Mn) Forecast, By Distribution Channel, 2018–2033
Table 08: North America Market Size (US$ Mn) Forecast, by Country, 2018–2033
Table 09: Europe Market Size (US$ Mn) Forecast, by Drug Class, 2018–2033
Table 10: Europe Market Size (US$ Mn) Forecast, by Formulation, 2018–2033
Table 11: Europe Market Size (US$ Mn) Forecast, By Distribution Channel, 2018 and 2033
Table 12: Europe Market Size (US$ Mn) Forecast, by Country, 2018–2033
Table 13: Asia Pacific Market Size (US$ Mn) Forecast, by Drug Class, 2018–2033
Table 14: Asia Pacific Market Size (US$ Mn) Forecast, by Formulation, 2018–2033
Table 15: Asia Pacific Market Size (US$ Mn) Forecast, By Distribution Channel, 2018 and 2033
Table 16: Asia Pacific Market Size (US$ Mn) Forecast, by Country, 2018–2033
Table 17: Latin America Market Size (US$ Mn) Forecast, by Drug Class, 2018–2033
Table 18: Latin America Market Size (US$ Mn) Forecast, by Formulation, 2018–2033
Table 19: Latin America Market Size (US$ Mn) Forecast, By Distribution Channel, 2018–2033
Table 20: Latin America Market Size (US$ Mn) Forecast, by Country, 2018–2033
Table 21: Middle East and Africa Market Size (US$ Mn) Forecast, by Drug Class, 2018–2033
Table 22: Middle East and Africa Market Size (US$ Mn) Forecast, by Formulation, 2018–2033
Table 23: Middle East and Africa Market Size (US$ Mn) Forecast, By Distribution Channel, 2018 and 2033
Table 24: Middle East and Africa Market Size (US$ Mn) Forecast, by Country, 2018–2033
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Size (US$ Mn) Forecast, 2018–2033
Figure 02: Market Value Share, By Drug Class (2022)
Figure 03: Market Value Share, By Formulation (2022)
Figure 04: Market Value Share By, Distribution Channel (2022)
Figure 05: Market Value Share, By Region (2022)
Figure 06: Porter’s Five Force Analysis
Figure 07: Global Market Value Share Analysis, By Drug Class, 2022 and 2033
Figure 08: Global Proton Pump Inhibitor Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2033
Figure 09: Global H2 Antagonist Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2033
Figure 10: Global Acid Neutralizer Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2033
Figure 11: Market Attractiveness Analysis, By Drug Class
Figure 12: Global Market Value Share Analysis, By Formulation, 2022 and 2033
Figure 13: Global Tablet Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2033
Figure 14: Global Liquids Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2033
Figure 15: Global Powder Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2033
Figure 16: Global Others Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2033
Figure 17: Global Market Attractiveness Analysis, By Formulation
Figure 18: Global Market Value Share Analysis, By Distribution Channel, 2022 and 2033
Figure 19: Global Hospital Pharmacies Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2033
Figure 20: Global Retail Pharmacies Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2033
Figure 21: Global Others Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2033
Figure 22: Global Market Attractiveness Analysis, By Distribution Channel
Figure 23: Global Market Value Share, By Region, 2022 and 2033
Figure 24: Global Market Attractiveness Analysis, By Region Type
Figure 25: North America Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2018–2033
Figure 26: North America Market Attractiveness Analysis, By Country
Figure 27: North America Market Value Share Analysis, By Drug Class, 2022 and 2033
Figure 28: North America Market Value Share Analysis, By Formulation, 2022 and 2033
Figure 29: North America Market Value Share Analysis, By Distribution Channel, 2022 and 2033
Figure 30: North America Market Value Share Analysis, By Country, 2022 and 2033
Figure 31: North America Market Attractiveness Analysis, By Drug Class
Figure 32: North America Market Attractiveness Analysis, By Formulation
Figure 33: North America Market Attractiveness Analysis, By Distribution Channel
Figure 34: Europe Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2018–2033
Figure 35: Europe Market Attractiveness Analysis, By Country
Figure 36: Europe Market Value Share Analysis, By Drug Class, 2022 and 2033
Figure 37: Europe Market Value Share Analysis, By Formulation, 2022 and 2033
Figure 38: Europe Market Value Share Analysis, By Distribution Channel, 2022 and 2033
Figure 39: Europe Market Value Share Analysis, By Country, 2022 and 2033
Figure 40: Europe Market Attractiveness Analysis, By Drug Class
Figure 41: Europe Market Attractiveness Analysis, By Formulation
Figure 42: Europe Market Attractiveness Analysis, By Distribution Channel
Figure 43: Asia Pacific Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2018–2033
Figure 44: Asia Pacific Market Attractiveness Analysis, By Country
Figure 45: Asia Pacific Market Value Share Analysis, By Drug Class, 2022 and 2033
Figure 46: Asia Pacific Market Value Share Analysis, By Formulation, 2022 and 2033
Figure 47: Asia Pacific Market Value Share Analysis, By Distribution Channel, 2022 and 2033
Figure 48: Asia Pacific Market Value Share Analysis, By Country, 2022 and 2033
Figure 49: Asia Pacific Market Attractiveness Analysis, By Drug Class
Figure 50: Asia Pacific Market Attractiveness Analysis, By Formulation
Figure 51: Asia Pacific Market Attractiveness Analysis, By Distribution Channel
Figure 52: Latin America Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2018–2033
Figure 53: Latin America Market Attractiveness Analysis, By Country
Figure 54: Latin America Market Value Share Analysis, By Drug Class, 2022 and 2033
Figure 55: Latin America Market Value Share Analysis, By Formulation, 2022 and 2033
Figure 56: Latin America Market Value Share Analysis, By Distribution Channel, 2022 and 2033
Figure 57: Latin America Market Value Share Analysis, By Country, 2022 and 2033
Figure 58: Latin America Market Attractiveness Analysis, By Drug Class
Figure 59: Latin America Market Attractiveness Analysis, By Formulation
Figure 60: Latin America Market Attractiveness Analysis, By Distribution Channel
Figure 61: Middle East and Africa Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2018–2033
Figure 62: Middle East and Africa Market Attractiveness Analysis, By Country
Figure 63: Middle East and Africa Market Value Share Analysis, By Drug Class, 2022 and 2033
Figure 64: Middle East and Africa Market Value Share Analysis, By Formulation, 2022 and 2033
Figure 65: Middle East and Africa Market Value Share Analysis, By Distribution Channel, 2022 and 2033
Figure 66: Middle East and Africa Market Value Share Analysis, By Country, 2022 and 2033
Figure 67: Middle East and Africa Market Attractiveness Analysis, By Drug Class
Figure 68: Middle East and Africa Market Attractiveness Analysis, By Formulation
Figure 69: Middle East and Africa Market Attractiveness Analysis, By Distribution Channel
Figure 70: AstraZeneca, Breakdown of Net Sales (%), by Region, 2022
Figure 71: AstraZeneca, Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022
Figure 72: Bayer AG, Breakdown of Net Sales (%), by Region, 2022
Figure 73: Bayer AG, Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022
Figure 74: Boehringer Ingelheim, Break down of Net Sales (%), by Region, 2022
Figure 75: Boehringer Ingelheim, Revenue (US$ Mn) & Y-o-Y Growth (%), 2018–2022
Figure 76: Dr. Reddy’s, Breakdown of Net Sales (%), by Region, 2022
Figure 77: Dr. Reddy’s, Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022
Figure 78: GlaxoSmithKline, Breakdown of Net Sales (%), by Region, 2022
Figure 79: GlaxoSmithKline, Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022
Figure 80: Johnson & Johnson, Break down of Net Sales (%), by Region, 2022
Figure 81: Johnson & Johnson, Revenue (US$ Mn) and Y-o-Y Growth (%), 2018-2022
Figure 82: Pfizer Inc., Breakdown of Net Sales (%), by Region, 2022 (%)
Figure 83: Pfizer Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022
Figure 84: P&G, Breakdown of Net Sales (%), by Region, 2022
Figure 85: P&G, Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022
Figure 86: Reckitt Benckiser, Breakdown of Net Sales (%), by Region, 2022
Figure 87: Reckitt Benckiser, Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022
Figure 88: Sanofi, Breakdown of Net Sales (%), by Region, 2022
Figure 89: Sanofi, Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022
Figure 90: Breakdown of Net Sales (%), by Region, 2022
Figure 91: Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2022
Figure 92: Takeda Pharmaceutical, Break down of Net Sales (%), by Region, 2022
Figure 93: Takeda Pharmaceutical, Revenue (US$ Bn) & Y-o-Y Growth (%), 2018–2022
Figure 94: Valeant Pharmaceuticals International, Inc., Break down of Net Sales (%), by Region, 2022
Figure 95: Valeant Pharmaceuticals International, Inc., Revenue (US$ Bn) & Y-o-Y Growth (%), 2018–2022
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the value of the antacids market in 2023?
The global antacids market is valued at US$ 14 billion in 2023.
How big will the market for antacids be by 2033?
Sales of antacids are set to reach US$ 22 billion by 2033.
What will the growth rate of the antacids market be from 2023 to 2033?
Demand for antacids is forecasted to increase at a CAGR of 4.6% through 2033.
Who are the key producers of antacids?
Bayer AG, GlaxoSmithKline plc, and Mylan N.V. are the top suppliers of antacids.
Which is the most dominant region in the global market?
At present, Europe holds 50% share of the global market for antacids.
Antacids Market